Literature DB >> 7883548

Anaplastic carcinoma of the thyroid: a 24-year experience.

R K Tan1, R K Finley, D Driscoll, V Bakamjian, W L Hicks, D P Shedd.   

Abstract

BACKGROUND: Anaplastic carcinoma of the thyroid gland is a lethal entity; few patients live more than 12 months following diagnosis. We retrospectively reviewed the experience with this entity at our cancer institute and identified a subgroup of patients with complete resection who have a 60% 5-year survival.
METHODS: Twenty-one cases of anaplastic carcinoma of the thyroid gland were analyzed retrospectively with respect to prognostic factors influencing survival. This represents 2.7% of 771 cases of thyroid cancer seen at our institution from 1968 to 1992. The median age at presentation was 65.1 years; male/female ratio was 1:1.1; and the most common symptom was a rapidly enlarging neck mass (76%).
RESULTS: Estimated 5-year survival was 10% (median: 4.5 months). Tumor size less than 6.0 cm (p = .004) and female gender (p = .02) were significant prognostic factors. Five patients who underwent complete resection had an estimated 5-year survival of 60% (median: 131 months). Four of these patients had postoperative radiotherapy with or without sequential chemotherapy. Two of these patients survived more than 10 years, and a third remains alive without disease at 26 months.

Entities:  

Mesh:

Year:  1995        PMID: 7883548     DOI: 10.1002/hed.2880170109

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  43 in total

Review 1.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

2.  Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.

Authors:  Akira Yoshida; Kiminori Sugino; Iwao Sugitani; Akira Miyauchi
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

Review 3.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

4.  Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).

Authors:  Amjad Husain; Nina Hu; Peter M Sadow; Carmelo Nucera
Journal:  Cancer Lett       Date:  2015-07-17       Impact factor: 8.679

5.  Anaplastic thyroid carcinoma presenting as bilateral pleural effusion.

Authors:  R Sodhi; G Sindhwani; S Chandra; D Anand
Journal:  Lung India       Date:  2014-07

Review 6.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

7.  Anaplastic thyroid carcinoma: a therapeutic dilemma.

Authors:  Hang-Seok Chang; Kee-Hyun Nam; Woung Youn Chung; Cheong Soo Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

8.  Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers.

Authors:  David Tai; Donald Poon
Journal:  J Oncol       Date:  2010-08-24       Impact factor: 4.375

Review 9.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

Authors:  Patricia J McLaughlin; Ian S Zagon; Sunny S Park; Andrea Conway; Renee N Donahue; David Goldenberg
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.